Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individuals [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 1, 2000, Pages 95-96

  Gallego, O ^a   Briones, C ^a   Corral, A ^a   Soriano, V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; ZIDOVUDINE;

CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0034275159     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200009010-00015     Document Type: Letter

References (9)

1. Development of HIV-1 resistance to 2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex
2. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
3. A novel polymorphism at codon 333 of HIV-1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2', 3'-dideoxy-3'-thiacytidine
4. A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
5. High prevalence of multidrug resistance mutations in a UK HIV/AIDS patient population
6. Multiple dideoxynucleoside analogue-resistant HIV-1 strains isolated from patient from different European countries
7. Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues
8. A 6-basepair insert in the RT gene of HIV-1 confers resistance to multiple nucleoside inhibitors
9. Prevalence and genetic heterogeneity of the reverse transcriptase T69SSX insertion in pretreated HIV-infected patients